Unmet clinical need in autoimmune liver diseases

被引：54
作者：
Dyson, Jessica K. [1 ]
Webb, Gwilym [2 ,3 ]
Hirschfield, Gideon M. [2 ,3 ,4 ]
Lohse, Ansgar [5 ]
Beuers, Ulrich [6 ]
Lindor, Keith [7 ]
Jones, David E. J. [1 ,4 ,8 ]
机构：
[1] Freeman Rd Hosp, Liver Unit, Newcastle Upon Tyne, Tyne & Wear, England
[2] Univ Birmingham, Liver Res Ctr, Birmingham B15 2TT, W Midlands, England
[3] Univ Birmingham, NIHR Biomed Res Unit, Birmingham B15 2TT, W Midlands, England
[4] UK PBC Res Consortium, Newcastle Upon Tyne, Tyne & Wear, England
[5] Univ Klinikum Eppendorf, Hamburg, Germany
[6] Amsterdam Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[7] Arizona State Univ, Med Ctr, Tempe, AZ 85287 USA
[8] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷 / 01期
基金：
英国医学研究理事会;
关键词：
Unmet clinical need; Autoimmune liver diseases; Primary biliary cirrhosis; Primary sclerosing cholangitis; Autoimmune hepatitis; IgG4; disease; Stratified care delivery; PRIMARY BILIARY-CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; DOSE URSODEOXYCHOLIC ACID; URINARY-TRACT-INFECTION; QUALITY-OF-LIFE; TRANSIENT ELASTOGRAPHY; BIOCHEMICAL RESPONSE; ANTIMITOCHONDRIAL ANTIBODIES; ANTICENTROMERE ANTIBODIES; INCREASED PREVALENCE;
D O I：
10.1016/j.jhep.2014.09.010
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Despite recent advances in understanding and treatment, there remain significant areas of unmet clinical need in each of the autoimmune liver diseases (AILDs). The evolving research landscape and emerging large patient cohorts are creating unique opportunities to translate science into new therapies and care pathways, with the potential to significantly improve the lives of AILD patients. However, the areas of unmet need represent real challenges, which need to be addressed, if this vision is to be realised. This review describes the areas of unmet need in AILD in adults relating to diagnostic and prognostic assessment, primary therapy, symptom management, trial design and delivery, and structured care delivery, with the aim of focusing future research prioritisation. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：208 / 218
页数：11
相关论文
共 106 条
[91]   MECHANISMS OF DISEASE IgG4-Related Disease [J].
Stone, John H. ;
Zen, Yoh ;
Deshpande, Vikram .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :539-551
[92]   Ursodeoxycholic Acid in Primary Sclerosing Cholangitis: If Withdrawal Is Bad, Then Administration Is Good (Right?) [J].
Tabibian, James H. ;
Lindor, Keith D. .
HEPATOLOGY, 2014, 60 (03) :785-788
[93]  
TEMPERO MA, 1987, CANCER RES, V47, P5501
[94]   Autoimmune Hepatitis and Liver Transplantation: Indications, Results, and Management of Recurrent Disease [J].
Tripathi, Dhiraj ;
Neuberger, James .
SEMINARS IN LIVER DISEASE, 2009, 29 (03) :286-296
[95]   Treatment of autoimmune liver disease: current and future therapeutic options [J].
Trivedi, Palak J. ;
Hirschfield, Gideon M. .
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2013, 4 (03) :119-141
[96]   Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid [J].
Tsuda, Masanobu ;
Moritoki, Yuki ;
Lian, Zhe-Xiong ;
Zhang, Weici ;
Yoshida, Katsunori ;
Wakabayashi, Kanji ;
Yang, Guo-Xiang ;
Nakatani, Toshio ;
Vierling, John ;
Lindor, Keith ;
Gershwin, M. Eric ;
Bowlus, Christopher L. .
HEPATOLOGY, 2012, 55 (02) :512-521
[97]  
Turchany JM, 1997, AM J GASTROENTEROL, V92, P124
[98]   An increased risk of urinary tract infection precedes development of primary biliary cirrhosis [J].
Varyani, Fumi K. ;
West, Joe ;
Card, Timothy R. .
BMC GASTROENTEROLOGY, 2011, 11
[99]  
Vestergaard EM, 1999, CLIN CHEM, V45, P54
[100]   Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis - Overlapping or separate diseases? [J].
Webster, George J. M. ;
Pereira, Stephen P. ;
Chapman, Roger W. .
JOURNAL OF HEPATOLOGY, 2009, 51 (02) :398-402
234567891011